Cargando…

AB079. Upregulation of DEPDC1B correlates with tumor progression and predicts a poor prognosis in prostate cancer

One of the challenges in prostate cancer (PCa) treatment is lacking biomarkers that could accurately predict PCa progression. The most widely used biomarkers for PCa was prostate-specific antigen (PSA) level. However, PSA testing had low specificity for prostate cancer due to some other kinds of dis...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Feilun, Hu, Jiangpeng, Tan, Jian, Tang, Huaming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5565543/
http://dx.doi.org/10.21037/tau.2017.s079
_version_ 1783258397853876224
author Cui, Feilun
Hu, Jiangpeng
Tan, Jian
Tang, Huaming
author_facet Cui, Feilun
Hu, Jiangpeng
Tan, Jian
Tang, Huaming
author_sort Cui, Feilun
collection PubMed
description One of the challenges in prostate cancer (PCa) treatment is lacking biomarkers that could accurately predict PCa progression. The most widely used biomarkers for PCa was prostate-specific antigen (PSA) level. However, PSA testing had low specificity for prostate cancer due to some other kinds of disease, such as PBH, could also induce PSA levels. Of note, PSA testing could not discriminate different stages of PCa. Although recently studies had identified a few genes including UHRF1, PCA3, PCAT-1 and PCAT-14showed PCa-associated dysregulation, there was still an urgent need to identify novel prognostic biomarkers for PCa. The DEPDC1B gene is located on chromosome 5. Previous studies indicated DEPDC1Bpalyed an important role in regulating cell cycle and migration. For example, Marchesi et al. found DEPDC1B was a cell-cycle-regulated gene by regulating the interplay between cell-cycle progression and de-adhesion events at the mitotic entry. In non-small cell lung cancer, ectopic expression of DEPDC1B enhanced migration and invasion of cancer cells via activating Wnt/β-catenin signaling. However, the clinical relevance and functional roles of DEPDC1B in PCa remain unclear. In this study, we found that the expression levels of DEPDC1B in PCa tissues were significantly higher than that in non-tumor tissues. Furthermore, our results showed DEPDC1B was upregulated in high pathology stage PCa. Kaplan-Meier analysis showed that Lower DEPDC1B expression level was associated with better survival of PCa patients. GO and KEGG pathway analysis of DEPDC1B co-expressed genes showed DEPDC1B played an important role in regulating PCa proliferation and cell cycle progression. We believed that this study will provide a potential new therapeutic and prognostic target for prostate cancer.
format Online
Article
Text
id pubmed-5565543
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-55655432017-09-01 AB079. Upregulation of DEPDC1B correlates with tumor progression and predicts a poor prognosis in prostate cancer Cui, Feilun Hu, Jiangpeng Tan, Jian Tang, Huaming Transl Androl Urol Printed Abstracts One of the challenges in prostate cancer (PCa) treatment is lacking biomarkers that could accurately predict PCa progression. The most widely used biomarkers for PCa was prostate-specific antigen (PSA) level. However, PSA testing had low specificity for prostate cancer due to some other kinds of disease, such as PBH, could also induce PSA levels. Of note, PSA testing could not discriminate different stages of PCa. Although recently studies had identified a few genes including UHRF1, PCA3, PCAT-1 and PCAT-14showed PCa-associated dysregulation, there was still an urgent need to identify novel prognostic biomarkers for PCa. The DEPDC1B gene is located on chromosome 5. Previous studies indicated DEPDC1Bpalyed an important role in regulating cell cycle and migration. For example, Marchesi et al. found DEPDC1B was a cell-cycle-regulated gene by regulating the interplay between cell-cycle progression and de-adhesion events at the mitotic entry. In non-small cell lung cancer, ectopic expression of DEPDC1B enhanced migration and invasion of cancer cells via activating Wnt/β-catenin signaling. However, the clinical relevance and functional roles of DEPDC1B in PCa remain unclear. In this study, we found that the expression levels of DEPDC1B in PCa tissues were significantly higher than that in non-tumor tissues. Furthermore, our results showed DEPDC1B was upregulated in high pathology stage PCa. Kaplan-Meier analysis showed that Lower DEPDC1B expression level was associated with better survival of PCa patients. GO and KEGG pathway analysis of DEPDC1B co-expressed genes showed DEPDC1B played an important role in regulating PCa proliferation and cell cycle progression. We believed that this study will provide a potential new therapeutic and prognostic target for prostate cancer. AME Publishing Company 2017-08 /pmc/articles/PMC5565543/ http://dx.doi.org/10.21037/tau.2017.s079 Text en 2017 Translational Andrology and Urology. All rights reserved.
spellingShingle Printed Abstracts
Cui, Feilun
Hu, Jiangpeng
Tan, Jian
Tang, Huaming
AB079. Upregulation of DEPDC1B correlates with tumor progression and predicts a poor prognosis in prostate cancer
title AB079. Upregulation of DEPDC1B correlates with tumor progression and predicts a poor prognosis in prostate cancer
title_full AB079. Upregulation of DEPDC1B correlates with tumor progression and predicts a poor prognosis in prostate cancer
title_fullStr AB079. Upregulation of DEPDC1B correlates with tumor progression and predicts a poor prognosis in prostate cancer
title_full_unstemmed AB079. Upregulation of DEPDC1B correlates with tumor progression and predicts a poor prognosis in prostate cancer
title_short AB079. Upregulation of DEPDC1B correlates with tumor progression and predicts a poor prognosis in prostate cancer
title_sort ab079. upregulation of depdc1b correlates with tumor progression and predicts a poor prognosis in prostate cancer
topic Printed Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5565543/
http://dx.doi.org/10.21037/tau.2017.s079
work_keys_str_mv AT cuifeilun ab079upregulationofdepdc1bcorrelateswithtumorprogressionandpredictsapoorprognosisinprostatecancer
AT hujiangpeng ab079upregulationofdepdc1bcorrelateswithtumorprogressionandpredictsapoorprognosisinprostatecancer
AT tanjian ab079upregulationofdepdc1bcorrelateswithtumorprogressionandpredictsapoorprognosisinprostatecancer
AT tanghuaming ab079upregulationofdepdc1bcorrelateswithtumorprogressionandpredictsapoorprognosisinprostatecancer